These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes.
    Author: Dezii CM, Kawabata H, Tran M.
    Journal: South Med J; 2002 Jan; 95(1):68-71. PubMed ID: 11827247.
    Abstract:
    BACKGROUND: We evaluated differences in adherence and persistence with prescribed therapy of once-daily (OD) dosing compared with twice-daily (BID) dosing of glipizide in patients with type 2 diabetes. METHODS: The study cohort was derived from a pharmacy benefit manager claims database. Patients new to extended-release gastrointestinal therapeutic system (GITS) and immediate-release glipizide therapy were identified and followed for 1 year. Adherence indices (AIs) were calculated and persistence curves were constructed. RESULTS: Adherence indices rates were 60.5% in the GITS OD cohort and 52.0% in the BID cohort. Rates of persistence at 12 months were 44.4% in the GITS OD cohort vs 35.8% in the BID cohort. CONCLUSION: Initiation of OD pharmacotherapy results in better adherence and persistence compared with a BID regimen, despite a greater daily pill burden in the OD cohort. These data suggest that dosing frequency exerts a greater impact on patient adherence and persistence than number of tablets per dose.
    [Abstract] [Full Text] [Related] [New Search]